Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | LMNA | P02545 | 4/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | TP53 | P04637 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | THRB | P10828 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | EDNRB | P24530 | 3/20 | 0.34 |
| ▸ | EDNRA | P25101 | 3/20 | 0.34 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13041133 | 0.92 | MAPT (0.43) | MAPTALDH1A1LMNAKMT2AHPGD | |
| SCHEMBL10189762 | 0.86 | MAPT (0.39) | MAPTALDH1A1LMNAKMT2AHPGD | |
| SCHEMBL3297139 | 0.85 | ALDH1A1 (0.45) | MAPTALDH1A1LMNAKMT2AHPGD | |
| SCHEMBL10189760 | 0.84 | ALDH1A1 (0.38) | MAPTALDH1A1LMNAKMT2AHPGD | |
| SCHEMBL10189763 | 0.84 | MAPT (0.40) | MAPTALDH1A1LMNAKMT2AHPGD | |
| SCHEMBL10189767 | 0.84 | ERN1 (0.42) | MAPTALDH1A1LMNAKMT2AHPGD | |
| SCHEMBL410022 | 0.84 | MAPT (0.42) | MAPTALDH1A1LMNAKMT2AHPGD | |
| SCHEMBL411315 | 0.84 | MAPT (0.42) | MAPTALDH1A1LMNAKMT2AHPGD | |
| SCHEMBL411316 | 0.84 | ALDH1A1 (0.44) | MAPTALDH1A1LMNAKMT2AHPGD | |
| SCHEMBL15158945 | 0.83 | MAPT (0.38) | MAPTALDH1A1LMNAKMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9175022-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2015-11-03 | — | — | US | disclosed |
| US-8501790-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2013-08-06 | — | — | US | disclosed |
| US-20120022118-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022118-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | RB1, MKI67, MAPRE1 | MAPT 95/4885ALDH1A1 1872/4885LMNA 2274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.